Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Vertex Pharmaceuticals / Equity Bottom-Up

<ul><li>Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic direction.</li><li>The company reported total revenue of $2.77 billion, marking a 3% increase compared to the same period in 2024.</li><li>This growth was primarily driven by strong demand in the U.S., particularly for the cystic fibrosis (CF) treatment ALYFTREK, which gained FDA approval recently.</li></ul>

Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic direction.The company reported total revenue of $2.77 billion, marking a 3% increase compared to the same period in 2024.This growth was primarily driven by strong demand in the U.S., particularly for the cystic fibrosis (CF) treatment ALYFTREK, which gained FDA approval recently.

Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes!

<ul><li>Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024.</li><li>The company reported record revenues, attributed primarily to the sustained commercial success of its cystic fibrosis (CF) treatments and the initiation of CASGEVY's launch.</li><li>Vertex's total product revenue for the fourth quarter reached $2.91 billion, marking a 16% increase from the prior year, while full-year revenues surpassed $11 billion, reflecting a 12% growth rate.</li></ul>

Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024.The company reported record revenues, attributed primarily to the sustained commercial success of its cystic fibrosis (CF) treatments and the initiation of CASGEVY's launch.Vertex's total product revenue for the fourth quarter reached $2.91 billion, marking a 16% increase from the prior year, while full-year revenues surpassed $11 billion, reflecting a 12% growth rate.

Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For  Growth Trajectory!

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. </li>
<li>According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.</li>
<li>Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.</li>
</ul>


The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. 
According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.
Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.


Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

<ul><li>Vertex Pharmaceuticals recently reported its third-quarter earnings for 2024, presenting a picture of solid financial performance alongside significant advancements in its pipeline and product launches.</li><li>Financially, Vertex Pharmaceuticals reported a 12% year-over-year increase in revenue, reaching $2.77 billion for the third quarter.</li><li>This growth was underpinned by robust performance both in the U.S. and international markets, with U.S. revenues rising by 10% and international sales by 14%.</li></ul>

Vertex Pharmaceuticals recently reported its third-quarter earnings for 2024, presenting a picture of solid financial performance alongside significant advancements in its pipeline and product launches.Financially, Vertex Pharmaceuticals reported a 12% year-over-year increase in revenue, reaching $2.77 billion for the third quarter.This growth was underpinned by robust performance both in the U.S. and international markets, with U.S. revenues rising by 10% and international sales by 14%.

Vertex Pharmaceuticals: Its Efforts Towards Diversification with New Product Launches & Other Major Drivers

<ul><li>Vertex Pharmaceuticals displayed robust performance in the second quarter of 2024, marked by significant progress across its various operational and developmental sectors.</li><li>The company's revenue for the quarter was $2.65 billion, representing a 6% increase year-over-year.</li><li>Most notably, Vertex has raised its full-year product revenue guidance to between $10.65 billion and $10.85 billion, indicating a projected growth of approximately 9% compared to 2023.</li></ul>

Vertex Pharmaceuticals displayed robust performance in the second quarter of 2024, marked by significant progress across its various operational and developmental sectors.The company's revenue for the quarter was $2.65 billion, representing a 6% increase year-over-year.Most notably, Vertex has raised its full-year product revenue guidance to between $10.65 billion and $10.85 billion, indicating a projected growth of approximately 9% compared to 2023.

Vertex Pharmaceuticals: Advancements in Rare Disease Treatments & Overall Pipeline Development Driving Growth! - Major Drivers

United States

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments.  The Company develops drugs for the treatment of cystic fibrosis, autoimmune diseases, cancer, inflammatory bowel disease, and neurological disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vertex Pharmaceuticals (VRTX US)

Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes!

Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic...

Baptista Research

Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For Growth Trajectory!

Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024. The...

Baptista Research

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Vertex Pharmaceuticals: Its Efforts Towards Diversification with New Product Launches & Other Major Drivers

Vertex Pharmaceuticals recently reported its third-quarter earnings for 2024, presenting a picture of solid financial performance alongside...

Baptista Research

Vertex Pharmaceuticals: Advancements in Rare Disease Treatments & Overall Pipeline Development Driving Growth! - Major Drivers

Vertex Pharmaceuticals displayed robust performance in the second quarter of 2024, marked by significant progress across its various operational...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes!

Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic...

Baptista Research

Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For Growth Trajectory!

Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024. The...

Baptista Research

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

​Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Vertex Pharmaceuticals: Its Efforts Towards Diversification with New Product Launches & Other Major Drivers

Vertex Pharmaceuticals recently reported its third-quarter earnings for 2024, presenting a picture of solid financial performance alongside...

Baptista Research

Vertex Pharmaceuticals: Advancements in Rare Disease Treatments & Overall Pipeline Development Driving Growth! - Major Drivers

Vertex Pharmaceuticals displayed robust performance in the second quarter of 2024, marked by significant progress across its various operational...

Baptista Research

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...